AU2020331020A1 - Methods to detect MTBR tau isoforms and use thereof - Google Patents

Methods to detect MTBR tau isoforms and use thereof Download PDF

Info

Publication number
AU2020331020A1
AU2020331020A1 AU2020331020A AU2020331020A AU2020331020A1 AU 2020331020 A1 AU2020331020 A1 AU 2020331020A1 AU 2020331020 A AU2020331020 A AU 2020331020A AU 2020331020 A AU2020331020 A AU 2020331020A AU 2020331020 A1 AU2020331020 A1 AU 2020331020A1
Authority
AU
Australia
Prior art keywords
tau
seq
mtbr
species
csf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020331020A
Other languages
English (en)
Inventor
Nicolas BARTHELEMY
Randall Bateman
Kanta HORIE
Chihiro Sato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Washington University in St Louis WUSTL
Original Assignee
Washington University in St Louis WUSTL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Washington University in St Louis WUSTL filed Critical Washington University in St Louis WUSTL
Publication of AU2020331020A1 publication Critical patent/AU2020331020A1/en
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/34—Purifying; Cleaning
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
AU2020331020A 2019-08-13 2020-08-13 Methods to detect MTBR tau isoforms and use thereof Pending AU2020331020A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962886165P 2019-08-13 2019-08-13
US62/886,165 2019-08-13
US202062970950P 2020-02-06 2020-02-06
US62/970,950 2020-02-06
US202063044836P 2020-06-26 2020-06-26
US63/044,836 2020-06-26
PCT/US2020/046224 WO2021030615A1 (en) 2019-08-13 2020-08-13 Methods to detect mtbr tau isoforms and use thereof

Publications (1)

Publication Number Publication Date
AU2020331020A1 true AU2020331020A1 (en) 2022-03-03

Family

ID=74570452

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020331020A Pending AU2020331020A1 (en) 2019-08-13 2020-08-13 Methods to detect MTBR tau isoforms and use thereof

Country Status (10)

Country Link
US (1) US20220299527A1 (enExample)
EP (1) EP4013772A4 (enExample)
JP (2) JP7780200B2 (enExample)
KR (1) KR20220062287A (enExample)
CN (1) CN114555631A (enExample)
AU (1) AU2020331020A1 (enExample)
CA (1) CA3147548A1 (enExample)
IL (1) IL290492A (enExample)
MX (1) MX2022001817A (enExample)
WO (1) WO2021030615A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4096694A4 (en) 2020-01-30 2024-01-24 Prognomiq Inc LUNG BIOMARKERS AND THEIR METHODS OF USE
CN117460954A (zh) * 2021-03-31 2024-01-26 华盛顿大学 作为tau蛋白病的生物标志物的CSF磷酸化tau和β-淀粉样蛋白概况
US20220328134A1 (en) 2021-03-31 2022-10-13 PrognomIQ, Inc. Multi-omic assessment
US12387508B2 (en) 2021-09-10 2025-08-12 PrognomIQ, Inc. Direct classification of raw biomolecule measurement data
AU2022341187A1 (en) 2021-09-13 2024-03-21 PrognomIQ, Inc. Enhanced detection and quantitation of biomolecules
WO2023220276A1 (en) * 2022-05-11 2023-11-16 Washington University METHODS TO DETECT Aβ PROTEOFORMS AND USE THEREOF
JP2023175325A (ja) * 2022-05-30 2023-12-12 学校法人順天堂 タウオパチーの鑑別診断法
WO2024107745A1 (en) * 2022-11-14 2024-05-23 Washington University Methods to detect csf mtbr-tau and uses thereof
CN118896992A (zh) * 2024-08-30 2024-11-05 南京质谱医学科技有限公司 p-Tau217蛋白或其片段的检测方法、试剂盒和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9518101B2 (en) * 2011-09-19 2016-12-13 Axon Neuroscience Se Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
CA2867338A1 (en) 2012-03-13 2013-09-19 Janssen Alzheimer Immunotherapy Oligomeric a.beta. in the diagnosis, prognosis, and monitoring of alzheimer's disease
WO2013181618A2 (en) * 2012-05-31 2013-12-05 The Trustees Of Columbia University In The City Of New York Methods to treat alzheimer's disease using apoe inhibitors
JP6345655B2 (ja) * 2012-07-03 2018-06-20 ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ タウに対する抗体
WO2014011972A1 (en) * 2012-07-13 2014-01-16 Bristol-Myers Squibb Company Tau immunoassay
US20150253341A1 (en) * 2014-02-10 2015-09-10 Merck Sharp & Dohme Corp. Quantification of tau in biological samples by immunoaffinity enrichment and mass spectrometry
EP3674711A3 (en) 2014-07-01 2020-10-28 Steven W. Graves Biomarkers and methods for determining risk factors for alzheimer's disease
US10830775B2 (en) * 2014-09-30 2020-11-10 Washington University Tau kinetic measurements
HRP20210124T1 (hr) * 2014-11-19 2021-03-19 Axon Neuroscience Se Humanizirana tau antitijela u alzheimerovoj bolesti
EA037092B1 (ru) * 2015-07-06 2021-02-04 Юсб Биофарма Срл Тау-связывающие антитела
WO2017053739A1 (en) 2015-09-25 2017-03-30 Steen Judith Methods and compositions for tauopathy diagnosis and treatment
WO2018148593A1 (en) * 2017-02-10 2018-08-16 C2N Diagnostics, Llc Methods for measuring concentrations of biomolecules in biofluids
CN112166117A (zh) * 2018-05-03 2021-01-01 华盛顿大学 基于位点特异性tau磷酸化的诊断和治疗方法

Also Published As

Publication number Publication date
KR20220062287A (ko) 2022-05-16
MX2022001817A (es) 2022-03-11
JP2026048659A (ja) 2026-03-17
CN114555631A (zh) 2022-05-27
JP2022544514A (ja) 2022-10-19
WO2021030615A1 (en) 2021-02-18
EP4013772A1 (en) 2022-06-22
JP7780200B2 (ja) 2025-12-04
US20220299527A1 (en) 2022-09-22
IL290492A (en) 2022-04-01
CA3147548A1 (en) 2021-02-18
EP4013772A4 (en) 2024-06-05

Similar Documents

Publication Publication Date Title
JP7780200B2 (ja) Ｍｔｂｒタウアイソフォームを検出する方法およびその使用
AU2019262220B2 (en) Methods of diagnosing and treating based on site-specific tau phosphorylation
US11402392B2 (en) Methods of treating based on site-specific tau phosphorylation
JP7668027B2 (ja) 部位特異的タウリン酸化をベースとする診断および処置のための血液ベースアッセイ
US20250147049A1 (en) Methods for detecting csf tau species with stage and progression of alzheimer's disease, and use thereof
US20230280357A1 (en) Csf phosphorylated tau and amyloid beta profiles as biomarkers of tauopathies
KR20250109226A (ko) Csf mtbr-타우 검출 방법 및 이의 용도
CN117355750A (zh) 检测阿尔茨海默病阶段和进展的csf tau物质的方法及其用途